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15 (GDS-15) at baseline and after 3 years. All analyses were 
adjusted for age, gender and education.  Results: In 606 par-
ticipants (41% women; mean age 75 years) without antide-
pressant medication, GDS-15 scores at baseline did not differ 
for participants with subclinical hypothyroidism (n = 47; 
GDS-15 score 1.75, 95% CI 1.29–2.20, p = 0.53) or subclinical 
hyperthyroidism (n = 13; GDS-15 score 1.64, 95% CI 0.78–
2.51, p = 0.96) compared to euthyroid participants (n = 546; 
mean GDS-15 score 1.60, 95% CI 1.46–1.73). After 3 years, 
compared to the euthyroid participants, changes in GDS-15 
scores did not differ for participants with subclinical hypo-
thyroidism (ΔGDS-15 score –0.03, 95% CI –0.50 to 0.44, p = 
0.83), while subclinical hyperthyroidism was associated with 
an increase in GDS scores (ΔGDS-15 score 1.13, 95% CI 0.32–
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 Abstract 
 Background: Subclinical hypothyroidism has been associ-
ated with depressive symptoms in cross-sectional studies, 
but prospective data and data on subclinical hyperthyroid-
ism are scarce.  Methods: In the Leiden substudy of the Pro-
spective Study of Pravastatin in the Elderly at Risk (PROSPER), 
thyroid-stimulating hormone and free T 4 levels were mea-
sured at baseline and repeated after 6 months in adults aged 
70–82 years with preexisting cardiovascular disease or 
known cardiovascular risk factors to define persistent thy-
roid functional status. Main outcome measures were depres-
sive symptoms, assessed with the Geriatric Depression Scale 
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1.93, p = 0.04). All results were similar for persistent subclin-
ical thyroid dysfunction.  Conclusions: In this largest pro-
spective study on the association of persistent subclinical 
thyroid dysfunction and depression, subclinical hypothy-
roidism was not associated with increased depressive symp-
toms among older adults at high cardiovascular risk. Persis-
tent subclinical hyperthyroidism might be associated with 
increased depressive symptoms, which requires confirma-
tion in a larger prospective study.  © 2015 S. Karger AG, Basel 
 Introduction 
 Subclinical thyroid dysfunction is biochemically de-
fined as abnormal thyroid-stimulating hormone (TSH) 
levels with normal free T 4 (fT 4 ) levels. Subclinical hypo-
thyroidism is characterized by elevated TSH levels, and 
subclinical hyperthyroidism by depressed TSH levels. 
Subclinical thyroid dysfunction is a common condition, 
especially among the elderly, with a prevalence reaching 
up to 18% for subclinical hypothyroidism  [1–3] and up to 
4% for subclinical hyperthyroidism  [4] .
 Subclinical thyroid dysfunction has been associated 
with neuropsychiatric problems such as cognitive dys-
function and depressive symptoms  [4] . Thyroid hor-
mones are well known to exert effects on metabolic activ-
ity in the adult brain  [5] , and the American Psychiatric 
Association guidelines suggest thyroid function measure-
ments in the evaluation of depressive symptoms  [6] . In 
addition, thyroid hormone supplementation may in-
crease the effectiveness of antidepressants in treatment of 
depression  [7, 8] . Some cross-sectional studies found an 
association with depressive symptoms for both subclini-
cal hypothyroidism  [9, 10] and subclinical hyperthyroid-
ism  [11] . Moreover, autoimmune thyroiditis, the most 
common cause of subclinical hypothyroidism among the 
elderly, has been shown to be more frequent in depressed 
patients than in healthy euthyroid individuals (20 vs. 5%) 
 [12] . However, only few studies have prospectively com-
pared euthyroidism with subclinical thyroid dysfunction 
and depression: two prospective studies found no asso-
ciation between subclinical hypothyroidism and depres-
sive symptoms, but one of these included only the very 
elderly, all being aged 85 years and older  [13] , and an-
other included only elderly men aged 70 years and older 
 [14] .
 Therefore, we assessed the association between sub-
clinical thyroid dysfunction and the development of de-
pressive symptoms in a post hoc substudy of the Prospec-
tive Study of Pravastatin in the Elderly at Risk (PROS-
PER)  [15] . In 606 men and women, we investigated the 
association of thyroid status at baseline and persistent 
thyroid status after 6 months with depressive symptoms 
during a mean follow-up period of 3.2 years.
 Subjects and Methods 
 Study Population 
 We analyzed the participants in a substudy  [16] of the PROS-
PER trial, a large international double-blinded randomized place-
bo-controlled clinical trial assessing the effect of pravastatin on the 
risk of cardiovascular and cerebrovascular events in elderly par-
ticipants during a mean follow-up period of 3 years. The design of 
the PROSPER study  [15, 17] has been described elsewhere. In sum-
mary, 5,804 men and women aged 70–82 years with preexisting 
cardiovascular or cerebrovascular disease or at high risk of devel-
oping such a disease were included in the PROSPER study. Par-
ticipants with Mini-Mental State Examination (MMSE) scores <24 
were excluded. Neither the current presence nor a history of de-
pression were specified as inclusion or exclusion criteria in the 
PROSPER study. Out of 1,100 eligible Dutch participants, 650 sub-
jects consented to participate in the nested MRI substudy of the 
PROSPER cohort  [16] and had both thyroid function and depres-
sive symptoms evaluated, the latter by the Geriatric Depression 
Scale 15 (GDS-15). 
 Thyroid Function 
 Details on the measurement of TSH and fT 4 levels within the 
PROSPER study have been described elsewhere  [18] . TSH and fT 4 
levels were measured at baseline and after 6 months using third-
generation immunoassays. The participants were categorized ac-
cording to TSH levels at baseline and at follow-up. Based on the 
recent literature and current guidelines, subclinical hyperthyroid-
ism was defined as TSH levels <0.45 mIU/l, and subclinical hypo-
thyroidism was defined as TSH levels  ≥ 4.5 mIU/l, with fT 4 within 
the reference range (12–18 pmol/l)  [19–22] . Participants with 
TSH levels  ≥ 0.45 mIU/l and <4.5 mIU/l were considered euthy-
roid. Subgroups of subclinical hypothyroidism were defined as 
TSH levels 4.5–10 and >10 mIU/l, while subgroups of subclinical 
hyperthyroidism were defined as TSH levels 0.1–0.44 and <0.1 
mIU/l  [2, 23] . As subclinical thyroid dysfunction may spontane-
ously revert to normal thyroid function over time  [24–26] , we 
used a follow-up measurement of thyroid function after 6 months 
to define participants with persistent subclinical thyroid dysfunc-
tion or persistent euthyroidism from baseline until 6 months of 
follow-up  [27] . 
 Depressive Symptoms 
 Depressive symptoms were assessed at baseline and after 3.2 
years of follow-up using the GDS-15  [28] , a tool developed spe-
cifically for elderly patients and validated for outpatient use  [29, 
30] . The GDS-15 consists of 15 ‘yes/no’ questions on functional 
and depressive mood symptoms, resulting in total scores ranging 
from 0 to 15, with higher scores indicative of more depressive 
symptoms. A recent systematic review on the accuracy of different 
screening instruments for depression in older hospitalized patients 
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found the GDS-15 to be the most validated test  [31] . It has been 
shown that it is a valid tool for measuring longitudinal changes in 
depressive symptoms  [32] . Based on the existing literature, a dif-
ference in GDS-15 scores of 0.5–2 points was considered clinically 
meaningful  [32, 33] . The use of antidepressant medication was as-
sessed at baseline.
 Statistical Analysis 
 Baseline characteristics were grouped according to thyroid sta-
tus (euthyroid, subclinical hypothyroidism and subclinical hyper-
thyroidism). Baseline characteristics of the groups with subclinical 
thyroid dysfunction were compared to those of the euthyroid 
group using two-sample t tests and χ 2 tests. Linear regression anal-
yses were performed to assess the cross-sectional association be-
tween subclinical thyroid status and depressive symptoms, adjust-
ing for age, gender and education (minimally adjusted model). In 
a multivariable adjusted model, we additionally adjusted for vas-
cular risk factors (defined as history of vascular disease, history of 
hypertension, history of diabetes mellitus, current smoking, and 
treatment with pravastatin or placebo).
 We also performed stratified analyses in which we investigated 
the subgroups of subclinical hypothyroidism and subclinical hy-
perthyroidism. Furthermore, we performed sensitivity analyses in 
which we (1) excluded participants on thyroxin or antithyroid 
medication at baseline, (2) included participants on antidepressant 
medications at baseline and (3) excluded participants taking up 
antidepressant medication during follow-up. Two-sided p values 
<0.05 were considered statistically significant. All analyses were 
conducted using SPSS (version 20.0; PASW Statistics Inc., Chica-
go, Ill., USA).
 Results 
 For the present analysis, we excluded 22 participants 
with overt thyroid dysfunction, 2 participants with miss-
ing GDS-15 scores at baseline and 20 participants on an-
tidepressant medication at baseline, yielding a final study 
sample of 606 participants ( fig. 1 ).
 Baseline Characteristics 
 The baseline characteristics are shown in  table 1 . Of all 
participants, 41.3% were female. The mean age of the 
study population was 75 years. A total of 13 participants 
(2.2%) had subclinical hyperthyroidism and 47 partici-
pants (7.8%) had subclinical hypothyroidism. Baseline 
characteristics did not differ between the subclinical thy-
roid dysfunction groups and the euthyroid group, except 
for the lower educational status, higher use of thyroxine 
medication, higher share of female participants and low-
er body height of the participants with subclinical hypo-
thyroidism, and the lower diastolic blood pressure in par-
ticipants with subclinical hyperthyroidism.
 Baseline Thyroid Status and Depressive Symptoms 
 Table 2 shows the association of baseline thyroid status 
with GDS-15 score at baseline and change in GDS-15 
n = 650
Thyroid function at baseline
Subclinical
hyperthyroidism
n = 13
Euthyroidism
n = 546
Subclinical
hypothyroidism
n = 47
Persistent thyroid function
Persistent subclinical
hyperthyroidism
n = 7
Persistent 
euthyroidism
n = 509
Persistent subclinical
hypothyroidism
n = 33
Exclusion of participants:
n = 2 with missing GDS-15 score
n = 20 participants taking
antidepressant medication
n = 0 with missing TSH/fT4 values at baseline
n = 7 with overt hypothyroidism
n = 15 with overt hyperthyroidism
 Fig. 1. Flowchart of the study participants. 
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 Table 1. Baseline characteristics of study participants by subclinical thyroid status
All
(n = 606)
Subclinical thyroid status  p value for difference
subclinical
hyperthyroidism
(n = 13)
euthyroidism
(n = 546)
subclinical
hypothyroidism
(n = 47)
subc linical 
hyperthyroidism 
vs. euthyroidism
subclinical 
hypothyroidism 
vs. euthyroidism
TSH level, mIU/l 2.38 ± 2.31 0.18 ± 0.15 1.97 ± 0.90 7.72 ± 5.29
fT4, pmol/l 16.46 ± 2.14 15.98 ± 1.37 16.62 ± 2.14 14.83 ± 1.57
Demographics
Female 250 (41.3) 8 (61.5) 214 (39.2) 28 (59.6) 0.10 0.01
Age, years 75.02 ± 3.21 75.17 ± 3.00 74.96 ± 3.20 75.66 ± 3.40 0.82 0.16
Age left school, years 15.45 ± 2.91 15.77 ± 3.44 15.52 ± 2.94 14.49 ± 2.24 0.77 0.01
GDS-15 score >4 56 (9.2) 1 (7.7) 7 (14.9) 48 (8.8) 0.89 0.17
Biometrics
Weight, kg 77.33 ± 11.93 71.73 ± 11.00 77.70 ± 12.08 74.60 ± 9.67 0.08 0.09
Height, cm 170.34 ± 8.55 166.08 ± 7.72 170.64 ± 8.65 167.96 ± 6.80 0.06 0.01
BMI 26.64 ± 3.61 25.94 ± 3.25 26.68 ± 3.68 26.42 ± 2.78 0.47 0.64
SBP, mm Hg 157.73 ± 21.76 146.46 ± 20.06 157.72 ± 21.51 161.02 ± 24.39 0.06 0.32
DBP, mm Hg 86.24 ± 11.51 79.85 ± 10.61 86.29 ± 11.64 87.36 ± 9.62 0.049 0.54
Risk factors
Current smoker 131 (21.6) 1 (7.7) 123 (22.5) 7 (14.9) 0.20 0.23
Excessive alcohol usea 60 (9.9) 0 (0.0) 57 (10.4) 3 (6.4) 0.22 0.38
History of diabetes 107 (17.7) 5 (38.5) 96 (17.6) 6 (12.8) 0.05 0.40
History of hypertension 377 (62.2) 8 (61.5) 337 (61.7) 32 (68.1) 0.99 0.39
History of vascular disease 273 (45.0) 6 (46.2) 241 (44.1) 21 (55.3) 0.89 0.14
History of TIA/stroke 98 (16.2) 2 (15.4) 87 (15.9) 9 (19.1) 0.96 0.57
Use of thyroxin 15 (2.5) 0 (0.0) 8 (1.5) 7 (14.9) 0.66 <0.001
Data represent means ± SD or n (%). BMI= Body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; TIA = 
transient ischemic attack. a Defined as >21 units per week for males and >14 units per week for females.
 Table 2. Association of baseline subclinical thyroid status with GDS-15 score
All
(n = 606)
Subclinical thyroid status p value for difference
subclinical
hyperthyroidism
(n = 13)
euthyroidism
(n = 546)
subclinical
hypothyroidism
(n = 47)
subclinical 
hyperthyroidism 
vs. euthyroidism
subclinical 
hypothyroidism 
vs. euthyroidism
At baseline
Minimally adjusted 1.66 (1.33, 1.99) 1.64 (0.78, 2.51) 1.60 (1.46, 1.73) 1.75 (1.29, 2.20) 0.96 0.53
Multivariable adjusted 1.74 (1.38, 2.10) 1.71 (0.84, 2.59) 1.70 (1.49, 1.91) 1.81 (1.32, 2.30) 0.95 0.64
Change in GDS-15 score during follow-upa
Minimally adjusted 0.27 (–0.07, 0.61) 0.81 (–0.80, 1.70) 0.03 (–0.10, 0.16) –0.03 (–0.50, 0.44) 0.09 0.83
Multivariable adjustedb 0.57 (0.24, 0.91) 1.13 (0.32, 1.93) 0.30 (0.11, 0.49) 0.30 (–0.15, 0.75) 0.04 0.98
Data represent means (95% CI). Higher scores mean more depressive symptoms. Minimally adjusted: adjusted for age, sex and education. Multivariable 
adjusted: additionally adjusted for history of vascular disease, history of hypertension, history of diabetes mellitus, current smoking and treatment with 
pravastatin or placebo. a Complete follow-up data were available for 510 participants (10 with subclinical hyperthyroidism, 464 with euthyroidism and 36 
with subclinical hypothyroidism). b Additionally adjusted for baseline GDS-15 score.
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score during follow-up. At baseline, there was no signifi-
cant difference in mean GDS-15 scores between euthy-
roid participants and participants with subclinical hyper-
thyroidism or hypothyroidism. During follow-up, partic-
ipants with subclinical hyperthyroidism showed a higher 
increase in GDS-15 score when compared to euthyroid 
participants, which only reached statistical significance in 
the multivariable adjusted model.
 Persistent Thyroid Status and Depressive Symptoms 
 Table 3 shows the association of persistent thyroid sta-
tus with GDS-15 score at baseline and change in GDS-15 
score during follow-up. A total of 33 out of 47 participants 
(70.2%) had subclinical hypothyroidism both at baseline 
and at 6 months of follow-up and were therefore defined 
as having persistent subclinical hypothyroidism. For sub-
clinical hyperthyroidism, a total of 7 out of 13 participants 
(53.8%) had this condition at baseline and at 6 months of 
follow-up and were defined as having persistent subclinical 
hyperthyroidism. There was no significant difference in 
mean GDS-15 score at baseline between persistent euthy-
roid participants and participants with persistent subclini-
cal hyperthyroidism or hypothyroidism. During follow-
up, the minimally adjusted model showed that participants 
with persistent subclinical hyperthyroidism had a nonsig-
nificant increase in GDS-15 score when compared to per-
sistent euthyroid participants. In the multivariable adjust-
ed model, this difference reached statistical significance.
 Stratified and Sensitivity Analyses 
 Stratification of TSH levels showed that subclinical hy-
perthyroidism participants with very low TSH levels 
(<0.1 mIU/l) at baseline had a significant increase in 
GDS-15 score after 3 years of follow-up when compared 
to euthyroid participants (difference in GDS-15 score: 
1.50, 95% CI 0.10–2.90, p = 0.04;  table 4 ); however, this 
subgroup included only a small sample of 5 participants. 
Analyses excluding participants on thyroid hormone 
 replacement (n = 15) and on antithyroid medication 
(n = 2) did not change our results (online suppl. table 1; 
see www.karger.com/doi/10.1159/000437387 for all on-
line suppl. material). The inclusion of 20 participants on 
antidepressant medication at baseline to the analyses did 
not materially change results either (online suppl. ta-
ble 2). Analyses excluding participants using antidepres-
sant medication during follow-up (overall: n = 41; 6.8%; 
2 with subclinical hyperthyroidism, 2 with subclinical hy-
pothyroidism) yielded similar results (online suppl. ta-
ble 3). A low number of participants developed an MMSE 
score <24 during follow-up (n = 20; 1 with subclinical 
hyperthyroidism, none with subclinical hypothyroid-
ism).
 Discussion 
 In this large prospective cohort study of 606 older 
adults, we found that both baseline and persistent sub-
clinical hypothyroidism were not associated with in-
creased depressive symptoms as assessed by the GDS-15. 
Conversely, results were consistent with a possible asso-
ciation between subclinical hyperthyroidism and in-
creased depressive symptoms. To our knowledge, this 
study is currently the largest prospective study on the as-
 Table 3. Association of persistent subclinical thyroid status with GDS-15 score
All
(n = 549)
Subclinical thyroid status p value for difference
subclinical
hyperthyroidism
(n = 7)
euthyroidism
(n = 509)
subclinical 
hypothyroidism
(n = 33)
subclinical 
hyperthyroidism 
vs. euthyroidism
subclinical 
hypothyroidism 
vs. euthyroidism
At baseline
Minimally adjusted 1.70 (1.27, 2.14) 1.86 (0.69, 3.02) 1.57 (1.43, 1.71) 1.68 (1.14, 2.22) 0.66 0.70
Multivariable adjusted 1.77 (1.31, 2.23) 1.97 (0.79, 3.15) 1.65 (1.44, 1.87) 1.68 (1.11, 2.25) 0.62 0.92
Change in GDS-15 score during follow-upa
Minimally adjusted 0.40 (0.00, 0.80) 1.00 (–0.07, 2.07) 0.02 (–0.11, 0.16) 0.17 (–0.37, 0.71) 0.07 0.59
Multivariable adjustedb 0.79 (0.41, 1.18) 1.53 (0.58, 2.49) 0.28 (0.09, 0.47) 0.56 (0.06, 1.06) 0.01 0.26
 Data represent means (95% CI). Higher differences mean more depressive symptoms. Minimally adjusted: adjusted for age, sex and education. 
Multivariable adjusted: additionally adjusted for history of vascular disease, history of hypertension, history of diabetes mellitus, current smoking and 
treatment with pravastatin or placebo. Difference in GDS-15 score is defined as GDS-15 score after 3 years of follow-up minus GDS-15 score at baseline.
a Complete follow-up data were available for 476 participants (7 with subclinical hyperthyroidism, 441 with euthyroidism and 28 with subclinical 
hypothyroidism). b Additionally adjusted for baseline GDS-15 score.
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sociation of persistent subclinical thyroid dysfunction 
with depression.
 The evidence on the association between subclinical 
hyperthyroidism and depressive symptoms in elderly 
people is scarce, and comparison is made difficult due to 
the use of diverse scales to assess depressive symptoms. 
One cross-sectional study (n = 3,756) found that depres-
sion was more prevalent in women who had a low serum 
TSH level (<0.4 mIU/l) among patients admitted to three 
psychiatric hospitals  [34] . However, in this cross-section-
al study, low TSH concentrations could be the conse-
quence rather than a cause of the psychiatric illness and 
hospitalization  [4] . One Turkish nonrandomized inter-
ventional study of 160 participants (13 with subclinical 
hyperthyroidism) found an improvement in depressive 
symptoms as assessed by the Hamilton Depression Rat-
ing Scale 9.1 months after treatment of subclinical hyper-
thyroidism with propylthiouracil  [35] . Conversely, in a 
small randomized controlled trial of 33 participants, de-
pressive symptoms showed an improvement after induc-
tion of exogenous subclinical hyperthyroidism over a fol-
low-up time of 12 weeks  [36] . Other large cross-sectional 
analyses (n = 254–30,589)  [37–39] found no association, 
and one population-based prospective study of 3,932 
 participants (31 with subclinical hyperthyroidism)  [14] 
found no association of subclinical hyperthyroidism with 
depressive episodes classified according to the ICD-9, 
suggesting that previous positive studies and our finding 
of increased depressive symptoms particularly in partici-
pants with very low TSH levels are possibly due to chance. 
To better understand the possible pathophysiological 
mechanisms of this association, future studies should 
 assess parameters of the hypothalamic-pituitary-adrenal 
axis, such as serum glucocorticoid levels, corticotropin-
releasing hormone and adrenocorticotropic hormone 
(not measured in the present study), since a previous 
study found that adults with depression had higher corti-
sol levels compared to control subjects without psychiat-
ric disorders  [40] . 
 Subclinical hypothyroidism has previously been asso-
ciated with depressive symptoms in smaller cross-sec-
tional studies (n = 323–583)  [9, 10] . In a recent study of 
323 participants over 60 years of age, subclinical hypo-
thyroidism was identified as a risk factor for depressive 
symptoms (OR 4.9, 95% CI 2.8–8.6)  [9] . However, sev-
eral large cross-sectional studies of elderly patients (n = 
3,932–30,589) found no association  [14, 39, 41] . This is 
in line with a prospective observational study of 558 pa-
tients aged over 85 years (n = 30 with subclinical hypo-
thyroidism defined by TSH >4.8 mIU/l and normal fT 4 ), 
which showed that over a mean follow-up time of 3.7 
years TSH and fT 4 levels were not associated with depres-
sive symptoms as assessed by the GDS-15  [13] . In an 
Australian population-based prospective study of 3,932 
men aged 70 years and older (31 with subclinical hyper-
thyroidism), baseline subclinical hypothyroidism was 
not associated with depression either cross-sectionally or 
prospectively. However, this study did not follow depres-
sion outcomes systematically in all participants, as inci-
dent depression disorders were assessed by collecting 
ICD-9-coded diagnoses through data linkage  [14] . The 
comparability of these findings is, however, limited, 
since current evidence suffers from the multitude of 
questionnaires, assessments and cutoffs used for the def-
 Table 4. Association of baseline subclinical thyroid status with GDS-15 score, stratified for very low and very high TSH values
All
(n = 606)
Subclinical hyperthyroidism Euthyroidism
(TSH
0.45 – 4.49 mIU/l;
n = 546)
Subclinical hypothyroidism p value for difference
TSH
<0.1 mIU/l
(n = 5)
TSH
0.1 – 0.45 mIU/l
(n = 8)
TSH
4.50 – 10 mIU/l
(n = 41)
TSH
>10 mIU/l
(n = 6)
TSH
<0.1 mIU/l 
vs. euthyr.
TSH
0.1 – 0.45 mIU/l
vs. euthyr.
TSH
4.50 – 10 mIU/l 
vs. euthyr.
TSH
>10 mIU/l 
vs. euthyr.
At baseline
Minimally adjusted 1.75
(1.30, 2.20)
1.89
(0.50, 3.29)
1.49
(0.38, 2.59)
1.60
(1.46, 1.73)
1.70
(1.21, 2.19)
2.08
(0.81, 3.36)
0.67 0.79 0.69 0.47
Multivariable adjusted 1.84
(1.36, 2.31)
2.02
(0.61, 3.42)
1.52
(0.40, 2.64)
1.70
(1.49, 1.91)
1.75
(1.23, 2.27)
2.20
(0.91, 3.49)
0.65 0.66 0.83 0.45
Change in GDS-15 score during follow-upa
Minimally adjusted 0.19
(–0.28, 0.66)
1.50
(0.10, 2.90)
0.34
(–0.80, 1.49)
0.03
(–0.10, 0.16)
0.10
(–0.40, 0.60)
–1.04
(–2.44, 0.36)
0.04 0.59 0.78 0.14
Multivariable adjustedb 0.59
(0.14, 1.04)
2.00
(0.73, 3.26)
0.53
(–0.51, 1.58)
0.29
(0.10, 0.48)
0.35
(–0.12, 0.82)
–0.21
(–1.48, 1.06)
0.01 0.66 0.80 0.45
 Data represent means (95% CI). Higher scores mean more depressive symptoms. Minimally adjusted: adjusted for age, sex and education. Multivariable adjusted: additionally 
 adjusted for history of vascular disease, history of hypertension, history of diabetes mellitus, current smoking and treatment with pravastatin or placebo. Difference in GDS-15 score 
is defined as GDS-15 score after 3 years of follow-up minus GDS-15 score at baseline. euthyr. = Euthyroidism. a Complete follow-up data were available for 510 participants (4 with 
TSH <0.1 mIU/l, 6 with TSH 0.1 – 0.45 mIU/l, 464 with euthyroidism, 32 with TSH 4.5 – 10 mIU/l and 4 with TSH >10 mIU/l). b Additionally adjusted for baseline GDS-15 score.
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inition of depression. Also, studies differ in the selection 
and characteristics of patients, such as age range and gen-
der. For example, in the abovementioned positive cross-
sectional study  [9] , participants were derived from inter-
nal medicine and psychiatry outpatient clinics and may 
have had more pronounced depressive symptoms than 
population-based study samples from some negative 
cross-sectional studies  [14, 39] . In addition, a small ran-
domized clinical trial assessing the effects of levothyrox-
ine replacement therapy versus placebo for 6 months in 
40 women with subclinical hypothyroidism (mean age 
49 years) found no significant change in the Hospital 
Anxiety and Depression Scale score in the intervention 
group, suggesting that thyroxine replacement therapy 
does not improve depression in women  [42] . Our find-
ings from a large prospective cohort add to the evidence 
that subclinical hypothyroidism is not associated with 
depression, at least in older adults.
 The present study has several limitations. The number 
of participants with subclinical hypothyroidism and par-
ticularly subclinical hyperthyroidism is relatively small, 
but to our knowledge, this is the largest prospective study 
assessing depressive symptoms associated with persistent 
subclinical hypothyroidism and subclinical hyperthy-
roidism in older men and women. The study population 
for this analysis was derived from a randomized con-
trolled trial of older patients at high cardiovascular risk or 
existing cardiovascular disease, which might limit the 
generalizability of our findings. On the other hand, both 
subclinical thyroid dysfunction and depression are prev-
alent in older age, which should increase the power to 
detect an association. In the present study, the GDS-15 
scores were generally relatively low, with only 5.2% of the 
participants having an elevated GDS-15 score (defined as 
>4) at baseline. Therefore, our data might not be general-
izable to patients with severe depression. The uptake of 
antidepressant medication during follow-up potentially 
influences results; however, the number of the partici-
pants requiring antidepressant medication was low, and 
a sensitivity analysis excluding these did not change re-
sults. We defined thyroid dysfunction by abnormal TSH 
and normal fT 4 levels, as has been done in other large 
population-based studies on the risks associated with thy-
roid dysfunction  [43–46] . Further parameters for assess-
ing thyroid function, such as T 3 levels, antithyroglobulin 
levels or thyroid ultrasound, were not available. Some 
participants with nonthyroidal illness may have been in-
cluded in the study, although inclusion was limited to 
community-dwelling elderly individuals who could at-
tend a clinical visit.
 The present study has several strengths. Most existing 
studies based their classification of participants on a sin-
gle baseline measurement of TSH and fT 4 only. However, 
subclinical hypothyroidism has been shown to resolve to 
normal TSH values without intervention over time  [24–
26] , which we addressed by using thyroid function mea-
surement after 6 months to define persistent subclinical 
thyroid dysfunction. We used a well-validated screening 
tool for depressive symptoms, which has been shown to 
be valid for the assessment of longitudinal changes as well 
 [32] . In addition, given the gradual course of depression, 
our mean follow-up duration of 3 years should be well 
suited to assess long-term changes of depressive symp-
toms.
 What are the clinical implications? According to cur-
rent guidelines, treatment of subclinical hyperthyroidism 
should be strongly considered if TSH is persistently <0.1 
mIU/l for those aged 65 years and older, and treatment 
should also be considered for this age group if TSH is low 
but  ≥ 0.1 mIU/l. Our results, showing an association of 
persistent subclinical hyperthyroidism with increased de-
pressive symptoms, are consistent with these recommen-
dations. Although evidence from observational data 
should be used with caution in clinical decision-making, 
no randomized controlled trial examined the impact of 
treating subclinical hyperthyroidism on depressive symp-
toms. 
 In conclusion, we found some evidence of an associa-
tion of persistent subclinical hyperthyroidism – but no 
evidence of an association of persistent subclinical hypo-
thyroidism – with increased depressive symptoms, at 
least among well-functioning older adults. The associa-
tion between persistent subclinical hyperthyroidism and 
increased depressive symptoms requires to be confirmed 
in a larger prospective study.
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